ACLS Provider: Course

Incorrect. Magnesium sulfate is used to treat torsades de pointes but is not the first-line drug for VF, where epinephrine is prioritized.

Incorrect. Compressing to one-third the depth of the chest ensures adequate perfusion while minimizing the risk of injury.

Incorrect. Hypokalemia can cause cardiac arrhythmias and is included in the "H's" of reversible causes of cardiac arrest.

Incorrect. Biphasic defibrillation begins at 120-200 J to terminate shockable rhythms like VF and pulseless VT effectively.

Incorrect. Naloxone is only used in cases of suspected opioid overdose and is not universally administered in cardiac arrest.

Incorrect. Oxygen saturation should be maintained at 92-96% to avoid hypoxia and reduce the risk of hyperoxia and oxidative stress.

Incorrect. Pulseless VT is a shockable rhythm requiring immediate defibrillation to restore organized cardiac activity.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J, restoring organized electrical activity.

Incorrect. With an advanced airway, compressions continue uninterrupted while ventilation is provided at a rate of 10 breaths per minute.

Incorrect. IM epinephrine is the first-line treatment for anaphylaxis, administered into the mid-thigh for rapid absorption.

Incorrect. A 30:2 ratio ensures adequate oxygenation and circulation when no advanced airway is present.

Incorrect. Atropine is the first-line drug for treating symptomatic bradycardia by increasing heart rate through vagal inhibition.

Incorrect. Epinephrine is dosed at 0.01 mg/kg IV/IO during pediatric cardiac arrest to improve coronary and cerebral perfusion.

Incorrect. Synchronized cardioversion restores organized cardiac activity in unstable VT with a pulse, preventing progression to VF.

Incorrect. Minimizes interruptions to maintain blood flow to vital organs.

Incorrect. Post-ROSC care focuses on maintaining oxygenation and avoiding hypoxia or hyperoxia to protect organ function.

Incorrect. Epinephrine is given first in VF during cardiac arrest, followed by amiodarone as an antiarrhythmic after defibrillation attempts.

Incorrect. Synchronized cardioversion with 120-200 J is used to restore normal rhythm in unstable atrial fibrillation.

Incorrect. A rate of 100-120 compressions per minute optimizes perfusion without compromising cardiac filling.

Incorrect. TTM is used to reduce neurological injury post-ROSC by maintaining a core temperature of 32-36°C.

Incorrect. Reduces the risk of oxidative stress and worsened outcomes by preventing hyperoxia.

Incorrect. The correct dose of epinephrine for pediatric cardiac arrest is 0.01 mg/kg IV/IO, not 1 mg/kg.

Incorrect. A rate of 100-120 compressions per minute ensures adequate circulation in pediatric patients.

Incorrect. Asystole is a non-shockable rhythm treated with high-quality CPR and epinephrine.

Incorrect. Compressing to a depth of 2-2.4 inches ensures adequate circulation without causing damage to internal organs.

Incorrect. Early defibrillation is critical for survival, especially in shockable rhythms like VF/VT.

Incorrect. Pediatric defibrillation starts at 2 J/kg and may increase to 4 J/kg for subsequent shocks if VF persists.

Incorrect. TTM prevents further neurological injury by maintaining a controlled core temperature after ROSC.

Incorrect. Asystole is not a shockable rhythm; it is treated with high-quality CPR and epinephrine.

Incorrect. Epinephrine 1 mg IV/IO is administered every 3-5 minutes during cardiac arrest to improve coronary and cerebral perfusion.

Incorrect. A PETCO2 reading above 10 mmHg indicates adequate chest compressions and cardiac output during CPR.

Incorrect. A 30:2 ratio ensures sufficient oxygenation and circulation in adults during CPR without an advanced airway.

Incorrect. Hypovolemia is a common reversible cause of PEA and should be addressed with rapid fluid resuscitation.

Incorrect. A left lateral tilt prevents aortocaval compression, improving venous return and cardiac output during resuscitation.

Incorrect. Defibrillation is the primary treatment for pulseless VT, aiming to restore organized cardiac activity.

Incorrect. Avoid delays to minimize interruptions in chest compressions and maintain perfusion.

Incorrect. Requires immediate defibrillation to restore organized cardiac activity.

Incorrect. CPR should be resumed immediately after defibrillation to maintain perfusion and increase the likelihood of ROSC.

Incorrect. Epinephrine is administered every 3-5 minutes during cardiac arrest to maximize coronary and cerebral perfusion.

Incorrect. Atrial flutter presents as a sawtooth pattern on the ECG and requires rate control or cardioversion depending on stability.

Incorrect. The same compression rate as adults ensures adequate perfusion in pediatric patients during CPR.

Incorrect. Amiodarone is administered as a 300 mg IV/IO bolus for refractory VF or pulseless VT.

Incorrect. Atropine is the first-line drug for symptomatic bradycardia, increasing heart rate by blocking vagal stimulation.

Incorrect. Needle decompression relieves pressure caused by tension pneumothorax, improving ventilation and circulation.

Incorrect. Asystole is a non-shockable rhythm requiring immediate CPR and epinephrine administration.

Incorrect. Immediate defibrillation is critical for shockable rhythms like ventricular fibrillation and pulseless VT.

Incorrect. Pediatric defibrillation starts at 2 J/kg, increasing to 4 J/kg for subsequent shocks if needed.

Incorrect. The compression fraction should be greater than 80% to maximize perfusion during CPR.

Incorrect. Chest compressions are performed to dislodge the obstruction and restore effective ventilation in an unresponsive infant.

Incorrect. Waveform capnography ensures proper ET tube placement by continuously monitoring exhaled CO? levels.

Incorrect. Atropine is given at a dose of 0.5 mg every 3-5 minutes during bradycardia, up to a maximum dose of 3 mg.

Incorrect. Synchronized cardioversion with 50-100 J is effective for narrow, regular tachycardias that are unstable.

Incorrect. Hypothermia is a reversible cause of cardiac arrest and is treated by warming the patient to improve outcomes.

Incorrect. Adenosine is used to terminate stable narrow-complex tachycardia by slowing AV node conduction.

Incorrect. A compression fraction >80% is required to maximize perfusion and improve survival rates during high-quality CPR.

Incorrect. A supine position ensures proper electrode placement and effective delivery of defibrillation shocks.

Incorrect. Magnesium sulfate is administered to stabilize the myocardium and terminate torsades de pointes.

Incorrect. This rate ensures effective circulation without causing inadequate ventricular filling.

Incorrect. Hypothermia is a reversible cause of cardiac arrest and must be corrected to restore spontaneous circulation.

Incorrect. Atropine blocks vagal stimulation, increasing heart rate in cases of symptomatic bradycardia.

Incorrect. The correct initial dose of amiodarone for pulseless VT is 300 mg IV/IO, followed by 150 mg for a second dose if needed.

Incorrect. If VF persists after defibrillation and epinephrine, amiodarone is administered to stabilize the rhythm.

Incorrect. Amiodarone 300 mg IV/IO is administered after defibrillation and epinephrine to treat refractory VF or pulseless VT.

Incorrect. Magnesium sulfate stabilizes the cardiac membrane and is the drug of choice for torsades de pointes.

Incorrect. With an advanced airway in place, compressions continue uninterrupted while breaths are delivered at 6-8 breaths per minute.